3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Melanoma
3
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
HIV Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
59
Nivolumab
19
atezolizumab
8
Ipilimumab
8
Docetaxel
7
avelumab
6
Paclitaxel
6
cemiplimab
5
Specimen Handling
5
Cyclophosphamide
5
Biopsy
5
Taxes
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Interleukin-2
4
Gemcitabine
4
Carboplatin
4
utomilumab
3
epacadostat
3
durvalumab
3
Radiotherapy
3
Cisplatin
3
Cetuximab
3
tremelimumab
2
tislelizumab
2
sargramostim
2
poly ICLC
2
obinutuzumab
2
fludarabine
2
enzalutamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Tumor Necrosis Factor-alpha
×
Dermatologic
×
Clear all
NCT05222932
2025-08-07
AVENTIL
TILT Biotherapeutics Ltd.
Phase 1
Active not recruiting
15 enrolled